Clinical Trial: Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07334119) titled 'Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors' on Nov. 14, 2025.

Brief Summary: This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are:

* What is the safety profile of MT-304 when administered alone or with nivolumab?

* What is the recommended Phase 2 dose (RP2D) of MT-304?

Participants will:

* Receive MT-304 alone (every 14 days) or with nivolumab (every 28 days).

* Attend regula...